<DOC>
	<DOCNO>NCT00150488</DOCNO>
	<brief_summary>This protocol describe multi-centre , community base open label study design ass efficacy safety intravesical sodium chrondroitin sulfate ( Uracyst® ) treatment patient clinical diagnosis interstitial cystitis ( IC ) . The safety study product evaluate incidence adverse event result physical examination laboratory test .</brief_summary>
	<brief_title>URACYST® For Treatment GAG Deficient Interstitial Cystitis</brief_title>
	<detailed_description>The primary efficacy endpoint percent responder treatment indicated improvement seven-point Patient Global Assessment scale week 10 ( 6 treatment ) compare baseline . The patient evaluate overall change condition markedly improve , moderately improve , slightly improve , change , slightly bad , moderately worse markedly bad . Secondary efficacy objective follow : 1 . Improvement individual IC symptom treatment period week 10 ( 6 treatment ) compare baseline . Pain urgency score ( 0-10 cm VAS ) obtain use patient on-site questionnaire prior first treatment ( baseline ) , week 4 , 6 , 10 , 14 , 18 , 22 24 . 2 . Change Patient Symptom/Problem Index score course treatment end study ( week 24 ) compare baseline . The validated O'Leary Symptom Problem/Index complete prior first treatment ( baseline ) week 4 , 6 , 10 , 14 , 18 , 22 24 . The validated PUF questionnaire complete prior first treatment ( baseline ) week 4 , 6 , 10 , 14 , 18 , 22 24 . 3 . Change patient condition every month throughout therapy treatment follow-up . In addition measure change patient condition week 14 , Patient Global Assessment complete week 4 , 6 , 10 , 14 , 18 , 22 24 .</detailed_description>
	<mesh_term>Cystitis</mesh_term>
	<mesh_term>Cystitis , Interstitial</mesh_term>
	<criteria>Patients must meet following eligibility criterion order enrol study . 1 . Clinical diagnosis interstitial cystitis 2 . Legally majority female capable willing provide inform consent 3 . Negative blood test pregnancy baseline assurance previous surgery , condition state render conception impossible 4 . A sterile bacterial urine culture thirty ( 30 ) day prior first treatment 5 . An average urinary frequency least 11 time per 24hour day 6 . An average pain/discomfort score 4 great 010cm VAS scale 7 . Available duration study include treatment followup ( 4 month ) 1 . Pregnant lactate 2 . Currently receive receive investigational drug thirty ( 30 ) day less prior screen 3 . Currently receive prior therapy intravesical treatment ( eg . Uracyst , Cystistat® , heparin BCG ) 4 . Receiving therapy less three month antidepressant , antihistaminics , hormonal agonist antagonist ; hence patient stabilized therapy . ( Stable therapy define continuous treatment least three month . ) 5 . Currently receive receive prior therapy oral pentosanpolysulfate ( Elmiron ) 3 month less prior screening 6 . IC symptom relieve antimicrobial , anticholinergic antispasmodic 7 . Bladder capacity great 500 ml awake cystometry use liquid fill medium 8 . Neurologic disease affect bladder function ; previous surgery procedure affect bladder function 9 . Current urinary tract infection ( must treat negative culture study entry ) 10 . Current diagnosis chemical , tuberculous radiation cystitis 11 . History bladder lower ureteral calculus 12 . History cancer within last five year adequately treat nonmelanoma skin cancer 13 . Active sexual transmit disease 14 . Current vaginitis 15 . Endometriosis 16 . Any condition/disease opinion investigator could interfere patient compliance and/ interfere interpretation treatment result</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2008</verification_date>
	<keyword>PBS</keyword>
	<keyword>Painful Bladder Syndrome</keyword>
	<keyword>Interstitial Cystitis</keyword>
	<keyword>chrondroitin sulfate</keyword>
</DOC>